Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 344

Posts Tagged ‘cancer’

Global In-vitro Colorectal Cancer Screening Tests Market 2019-2023

Posted by fidest press agency su martedì, 26 novembre 2019

The global in-vitro colorectal cancer screening tests market size is poised to grow by USD 219.61 million during 2019-2023, according to a new report by Technavio, progressing at a CAGR of close to 6% during the forecast period.
The market is driven by the growing awareness programs and government initiatives for cancer screening. Also, the increased rate of product approval is anticipated to further boost the growth of the in-vitro colorectal cancer screening tests market.The growing number of awareness programs and government initiatives will drive the market growth during the forecast period. Compulsory education and economic development are crucial in creating awareness about colorectal cancer screening. Early detection of colorectal cancer can improve outcomes. Mars Bleu was launched by NOVIGENIX as a national colorectal cancer awareness campaign and was dedicated to raising awareness about screening and preventing colorectal cancer in many countries. Moreover, in countries such as the US, government initiatives such as Colorectal Cancer Control Program and insurance policies like Medicaid and Medicare are working toward providing colorectal cancer screening tests to many patients.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

The American Association for Cancer Research Conference

Posted by fidest press agency su sabato, 23 novembre 2019

Omeros Corporation (Nasdaq: OMER) presented new GPR174 immuno-oncology data yesterday at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts. The positively received and well-attended presentation about the company’s cell-based and animal studies related to its newly discovered cancer immunity axis was made by Marc Gavin, Ph.D., Omeros’ Director of Immunology. This data can now be accessed on the company’s website at https://investor.omeros.com/presentations. Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-mediated disorders and substance abuse, as well as a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros’ proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Early Stage Lung Cancer at Innovation Summit San Francisco Conference

Posted by fidest press agency su domenica, 17 novembre 2019

Navigation Sciences™ will provide an update at the annual Medtech Strategist Innovation Summit San Francisco 2019 Conference on its Image Guided, Video Assisted Surgery (iVATS™) technology for the minimally invasive identification and removal of early stage lung cancer, the company announced today. The conference will take place in Burlingame, California on November 19, 2019.
The emergence of CT chest scanning as an effective tool in high risk populations to detect lung cancer at an early stage and lower cancer deaths is creating new opportunities to improve lung surgery. Removal of small tumors deep inside the lung with appropriate margins remains a significant challenge, as insufficient distance between the tumor and resection margin is associated with recurrence and death. Current surgical approaches either remove excess tissue via lobectomy, which lowers recurrence risk but results in more impaired lung function, or smaller, wedge resections, which reduces lung impairment but may increase recurrence risk.The Navigation Sciences™ solution integrates with multi-modal (imaging and surgery) technology and includes an active, GPS enabled marker (fiducial), proprietary, real-time navigation algorithms, and tumor cutting devices that allow for surgical precision specific to the patient’s anatomy. Radiology images are synchronized with real-time information to enable the clinician to perform surgery with precision guidance. The technology’s proof-of-concept was demonstrated in a Phase I-II clinical trial published in the Journal of Surgical Oncology. In the study, involving 25 patients (23 with early stage lung cancer), there were no significant complications, all nodules were fully resected with negative margins, and the technology was shown to integrate with surgical workflow.There are an estimated 87,000 patients in the U.S. diagnosed each year with early stage lung cancer and that number is expected to grow with growing recognition of CT X-ray screening’s value in early detection and favorable reimbursement coverage. Beyond lung cancer, the technology has significant potential in other soft tissue cancer surgeries including breast cancer, where an estimated 250,000 lumpectomies are performed annually, as well as liver, thyroid and brain tumors.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Breast Cancer Campaign

Posted by fidest press agency su sabato, 5 ottobre 2019

Every 15 seconds, somewhere in the world, a woman is diagnosed with breast cancer.1 That’s why, since 1992, The Estée Lauder Companies has been committed to saving lives – uniting and positively impacting people everywhere in its Breast Cancer Campaign’s mission to create a breast cancer-free world. For 27 years, The Estée Lauder Companies has inspired action, funding the world’s leading research to bring us closer to a cure and bringing a global level of awareness to the disease. It’s TimeToEndBreastCancer. The Estée Lauder Companies has been a leader in the global breast cancer movement since Evelyn H. Lauder co-created the Pink Ribbon and started The Breast Cancer Campaign (The Campaign) in 1992. A year later, in 1993, she founded the Breast Cancer Research Foundation® (BCRF), the highest-rated nonprofit breast cancer organization in the U.S., dedicated to advancing the world’s most promising research to eradicate breast cancer. The Campaign has raised more than $79 million to support global research, education and medical services through the collective support of consumers, employees and partners worldwide, with more than $65 million funding 260 medical research grants through BCRF. This year The Campaign aims to raise another $9 million globally.Real impact has been made and The Campaign is proudly part of that equation. Mortality rates from breast cancer have declined by 40% among women since the late 1980’s2 and BCRF-funded researchers have been involved in every major breakthrough in breast cancer prevention, diagnosis, treatment and survivorship. Breast cancer is spoken about more openly and important messages about early detection are saving lives – five-year survival rates are better than 90% with early detection.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

IQVIA Collaborates with Cancer Researchers to Advance Use of Real World Evidence

Posted by fidest press agency su sabato, 21 settembre 2019

IQVIA™ (NYSE:IQV) is proud to announce its collaboration with Friends of Cancer Research in a cross-industry effort to advance acceptance and drive future uses of real world evidence (RWE). This research helps confirm that clinical benefits seen for therapies in clinical trials were consistent with the benefits of those treatments within real world settings. RWE comprises dynamic data including assets such as EMR, hospital, pharmacy, and claims sources, as well as genomics, mobile health, and patient reported outcomes. The project is part of a Friends of Cancer Research initiative that is working to demonstrate the application of real world evidence in oncology research. As part of this project, a recent study involving six research centers in the U.S. followed a common protocol to assess real world endpoints among cancer patients, including overall survival, time to next treatment, time to treatment discontinuation, time to progression and progression-free survival. Results from the collaborative project, An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer, were recently published in JCO Clinical Cancer Informatics. Researchers used non-identified patient data from assets such as administrative claims and electronic health records to assess real world endpoints and found that they were generally consistent with each other and with outcomes observed in randomized clinical trials.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Henry Schein’s Practice Pink Program Supports the Global Fight Against Cancer

Posted by fidest press agency su sabato, 21 settembre 2019

Henry Schein, Inc. (Nasdaq: HSIC) today announced that it will again support nonprofit organizations dedicated to the fight against cancer through its Practice Pink™ program. Through the program, now in its 13th year, Henry Schein has donated more than $1.6 million towards promoting early cancer detection, improving access to care, and research and prevention efforts. Along with non-governmental organizations and supplier partners across North America and Europe, Henry Schein is helping dental and medical health care professionals raise awareness and support for a cure for breast cancer and other cancers by offering its customers a range of pink products, including health care consumables, practice supplies, and apparel. Practice Pink, an international effort, is an initiative of Henry Schein Cares, the Company’s global corporate social responsibility program.“The fight against cancer is everyone’s fight, and it is only by joining together and leveraging our collective strengths that our efforts will have the greatest effect,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “We at Team Schein thank our customers and supplier partners for their support of the Practice Pink program, and we look forward to continuing to work toward our shared goal of a world free of cancer.” The Practice Pink program supports U.S.-based organizations such as the American Cancer Society, Cohen Children’s Medical Center of Northwell Health, Stony Brook Children’s Hospital, and the Memorial Sloan Kettering/Henry Schein Cares Women’s Health Center. In Europe, the program supports organizations such as the Italian League for the Fight Against Cancer (LILT), Germany-based Brustkrebs Deutschland e.V., and Federacja Stowarzyszeń Amazonki in Poland.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Cancer Research Project Funded by Massachusetts Life Sciences Center Grant

Posted by fidest press agency su venerdì, 13 settembre 2019

Digital Health Impact – Aimed at offering more effective drugs at a lower cost to cancer patients turning to photomedicine as an alternative to chemotherapy, a grant from the Massachusetts Life Sciences Center (MLSC) will have chemical and data scientists working side by side at the Lopez Lab of Boston’s Northeastern University and the Cambridge facilities of Kebotix, an artificial intelligence technology company for new chemicals and materials.
“What makes this grant different from many others is it’s bringing industry and academics closer together, while importing top data scientists to Massachusetts to work on today’s most pressing life science problems,” said Dr. Steven Lopez, assistant professor of chemistry at Northeastern University.The project was among several announced today at Digital Health Impact 2019, a summit hosted by the Massachusetts Biotechnology Council that explores how life sciences companies may capitalize on the power of data and digital technologies in transforming drug development, discovery and patient care.Lopez’s research team uses high-throughput quantum mechanical computation to identify next-generation organic materials for applications in renewable energy and photomedicine. The results of these computations are open-access via Lopez’s website (web.northeastern.edu/lopezlab/verdedb). Partnering with Kebotix and its self-driving lab, the world’s first for materials discovery powered by machine learning algorithms for decision making and robots for synthesis and characterization, the Lopez Lab is expected to drastically accelerate development of multicolor chromophores used in cancer surgery and light-activated therapy.The partnership provides Northeastern University access to Kebotix’s autonomous lab capabilities and the team’s expertise in machine learning of materials properties.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

A study, Enhancing community capacity to deliver value-based cancer care at the end-of-life

Posted by fidest press agency su mercoledì, 11 settembre 2019

The study enrolled CareMore patients newly diagnosed with solid and hematologic malignancies from November 2016 through September 2018, and compared outcomes to a control group of all patients diagnosed with cancer in the year prior to intervention. The value-based cancer care model utilized LHWs, which are non-physician members of the community who have received specialized training to support the patient care and navigation. The study found there was no difference in survival between the groups, while the patients receiving the value-based care experienced better quality with end-of-life cancer care. The latter group had 40 percent lower inpatient admissions, 75 percent fewer emergency department visits in the last month of life, 45 percent increased hospice use, 40 percent fewer acute care facility deaths and 25 percent lower median total healthcare costs from diagnosis until death. “Through this study, the value-based care model developed by our group at Stanford and implemented by The Oncology Institute is associated with significant improvements in care for patients at the end of life,” said the study’s lead investigator, Manali Patel, MD, MPH, assistant professor of medicine at the Stanford University School of Medicine. “As providers, it’s important to support patient care with innovations that address patient’s needs and can improve patient experiences, while also lowering the total cost of care.” For all patients who died within 12 months, their risk of death was analyzed using Cox Models and generalized linear regression to compare healthcare use in the last month of life, and total costs of care from diagnosis until death. All models were adjusted for age, stage, comorbidities, diagnosis and length of follow-up.
“We are excited to collaborate with Stanford and with The Oncology Institute on this important study to implement impactful care redesign to improve the care and experience for this group of patients,” said Dr. Anil Hanuman, regional chief medical officer of CareMore Health. “CareMore specializes in treating high-risk patients requiring complex, acute and chronic care—including those battling cancer—and recognizes the impact this innovative model of care could potentially have on patients, their care – and on healthcare costs.” “This study is another proof point that the patient-centric and comprehensive care model developed at Stanford and implemented by The Oncology Institute and CareMore Health is the direction that the medical oncology model should be going,” said Richy Agajanian, MD, chief medical officer and senior regional director at TOI. “We are excited to provide this model of care to patients nationally as we continue to expand our partnerships with health care systems such as CareMore that are seeking to improve patient care and lower financial burden on patients through value-based oncology care.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Simple CEUS Scan Helps Diagnose Liver Cancer When MRI is Uncertain

Posted by fidest press agency su domenica, 8 settembre 2019

A new study shows that a simple, non-invasive “contrast enhanced ultrasound” (CEUS) scan can be more accurate and reliable than a more expensive MRI procedure for diagnosis of liver tumors and determining whether they are cancerous.The prospective study evaluated 42 patients at high risk for HCC, who were referred for CEUS imaging when their MRI scans over a six-month period, with 24-month follow-ups, were considered indeterminate.“These results significantly impact patients’ treatment and prognosis and reduce time to diagnosis,” Dr. Wilson said.
CEUS can be performed at a fraction of the cost of MRI or CT, and has an excellent, well-established safety profile, according to Dr. Ed Grant, Chair of the Department of Radiology at the University of Southern California Keck Hospital and Treasurer of ICUS.Ultrasound contrast agents are safely and routinely used throughout Canada, Europe, South America and Asia to image organs and tumors throughout the body, as well as to monitor chronic diseases and therapy. Today in the USA, they are FDA-approved for enhancing ultrasound images of the heart and liver in adults and children, but even without FDA approval physicians are permitted to use ultrasound contrast agents for “off-label” imaging when medically indicated. Further, organ-agnostic physician payment codes are now available as of January 1, 2019, Dr. Grant noted. An increasing body of studies now shows that “CEUS is often equivalent or superior to more expensive imaging tools like MR or CT, it allows for dynamic and repeat examinations, and unlike MRI and CT, it can be used in patients with kidney failure or allergy to iodinated contrast agents,” Dr. Wilson said.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

AscellaHealth Recognizes Blood, Prostate Health & Cancer Awareness Months

Posted by fidest press agency su venerdì, 6 settembre 2019

During September 2019, AscellaHealth, a national Pharmacy Benefit Management (PBM) serving commercial, Medicare and Medicaid segments, calls for increased awareness about how to manage the wide-ranging impact of a number of cancers and shows its support for Blood Cancer Awareness Month, encompassing leukemia, lymphoma, and myeloma, Prostate Health Month and Thyroid Cancer Awareness Month. The annual cost of treating blood cancer is $156,000 per patient in the first year following diagnosis, with high costs persisting beyond the first year. The typical cost of therapy for a prostate cancer patient is $2,800/month after diagnosis, primarily from surgery. The total cost of care for metastatic thyroid cancer can reach $60,000 or more in the first year and about $35,000 the following year.The AscellaHealth high-touch model focuses on better outcomes and care coordination for members living with cancer and offers discounted pricing to deliver value to payers and members. Its innovative specialty pharmacy strategy offers clinical interventions, adherence counseling, psychosocial assessment, integrated nursing staff, refill reminders and delivery coordination.
AscellaHealth’s program is available on a standalone basis, or as part of a full-service pharmacy benefit management option that includes specialty drug management, formulary management services/rebates, competitive pricing and innovative discounting, drug utilization review, case management services/therapy management, clinical review/prior authorization, pharmacy and therapeutic management committee, flexible claims adjudication system, drug information and news reporting.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

OncLive® Presents State of the Science Summit™ on Breast Cancer

Posted by fidest press agency su venerdì, 6 settembre 2019

OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with the most current and insightful information they need to offer the best patient care, will host its latest State of the Science Summit™ on Breast Cancer on Tuesday, Sept. 10 at 5 to 9 p.m. at the DoubleTree by Hilton Raleigh Durham Airport at Research Triangle Park. The summit will be chaired by P. Kelly Marcom, M.D., oncologist, professor in the department of medicine at Duke Cancer Institute.This interactive and educational meeting will explore the variety of novel treatment approaches for patients with breast cancer. Expert presenters will discuss topics facing breast cancer specialists, oncologists, nurses and other medical professionals, such as management of hormone receptive-positive/HER2-negative early stage disease, updates in metastatic hormone receptor-positive/HER2-negative disease, cardio-oncology in breast cancer, managing brain metastases in breast cancer, and HER2-positive breast cancer and triple-negative breast cancer. The presenters will also engage in a peer exchange and address questions from the audience.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

New Diagnostic Method Predicts Cancer Therapy Response

Posted by fidest press agency su giovedì, 29 agosto 2019

By using single-cell analysis to measure metabolic activities in rare disseminated tumor cells taken from non-small cell lung cancer (NSCLC) patients, Institute for Systems Biology (ISB) researchers and their collaborators can accurately predict how patients will respond to various cancer therapies, and how treatments will impact a patient’s physiological performance and survival. Additionally, researchers pinpointed the molecular basis underlying these metabolic states and identified potential treatment strategies for lung cancer patients who are unlikely to respond well to standard chemotherapies or targeted therapies. These results were published today in Nature Communications.“Our metabolic assay can provide unique information complementary to tumor genetics and other clinical factors for improved cancer diagnostics. For example, tumor genetics can identify whether the patients are bearing targetable driver oncogene mutations and thus segregate patients into various chemo- and targeted therapy regimens,” said Dr. Wei Wei, assistant professor at ISB and a corresponding author on the paper. “Our metabolic assay can further reveal whether patients are likely — or unlikely — to benefit from the standard chemo- or targeted therapies identified by tumor genetics. This is important particularly for newly diagnosed patients who may benefit from such predictions prior to the onset of therapy.” The single-cell metabolic assay developed in this work is simple, least invasive, and can, in principle, be performed in any clinical lab equipped with a fluorescence imaging system, and it has the potential to be democratized to regular cytopathology labs. It will provide highly complementary information to oncologists for more accurate clinical decision-making, thus saving valuable treatment time and releasing unnecessary burdens for patients who are less likely to respond well to standard clinical management and who might want to seek other (even more aggressive) treatment opportunities.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

MOLOGEN AG Announces Top Line Data of Pivotal IMPALA Study in Metastatic Colorectal Cancer

Posted by fidest press agency su giovedì, 8 agosto 2019

The biopharmaceutical company MOLOGEN AG (ISIN DE000A2LQ900, SIN A2L Q90) announced today the top line data of its pivotal phase III IMPALA study. The study compares the TLR9 agonist lefitolimod (MGN1703) with local standard of care as a maintenance therapy in patients with metastatic colorectal cancer presenting with an objective tumor response following first-line induction therapy. The primary endpoint – overall survival (OS) – was not met showing a median OS of 22.0 and 21.9 months in the lefitolimod and control group respectively (p=0.2765; HR=1.12; 95% CI 0.91 – 1.38). Timepoint related OS and predefined sub-group analyses did also not indicate a benefit, while regarding Progression Free Survival (PFS) standard of care was superior to lefitolimod treatment. No new safety signals were detected; hence the favorable safety and tolerability profile was confirmed. MOLOGEN is a pioneer in the field of immunotherapy, especially in the TLR9 field with the product family of DNA-based TLR9 agonists including its lead compound lefitolimod, as well as its follow-up molecules EnanDIM®. Given its mode of action and confirmed favorable safety profile, lefitolimod is being used as combination partner in anti-cancer and anti-HIV immunotherapies.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Cancer immunotherapy combination in previously untreated advanced bladder cancer

Posted by fidest press agency su mercoledì, 7 agosto 2019

Basel, Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMvigor130 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS). The combination of Tecentriq® (atezolizumab) plus platinum-based chemotherapy showed a statistically significant reduction in the risk of disease worsening or death (PFS) in people with previously untreated locally advanced or metastatic urothelial carcinoma (mUC) compared with chemotherapy alone. Encouraging overall survival (OS) results were observed at this interim analysis; however, these data are not yet mature and follow-up will continue until the next planned analysis.Safety in the Tecentriq plus chemotherapy arm appeared consistent with the known safety profiles of the individual medicines and no new safety signals were identified with the combination. Results will be presented at an upcoming medical meeting and shared with health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).Tecentriq was the first cancer immunotherapy approved in bladder cancer. Currently, there are four ongoing Phase III studies evaluating Tecentriq alone and in combination with other medicines in early and advanced bladder cancer. Roche has an extensive development programme for Tecentriq, including multiple ongoing and planned Phase III studies, across lung, genitourinary, skin, breast, gastrointestinal, gynaecological, and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Telix Pharmaceuticals and German Cancer Research Center

Posted by fidest press agency su martedì, 6 agosto 2019

MELBOURNE, Australia and HEIDELBERG, Germany (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has entered into a collaboration agreement with the German Cancer Research Center (Deutsches Krebsforschungszentrum or DKFZ) in the field of image-guided surgery for prostate cancer.
Researchers at DKFZ and Heidelberg University Clinic have developed a next-generation radiotracer based on 68Ga-PSMA-11 (currently under development by Telix as TLX591-CDx, marketed as illumetTM in the United States) that incorporates a fluorophore (a fluorescing agent) in addition to the ability to molecularly-target radiation for imaging with Positron Emission Tomography (PET). The result is a technology that can simultaneously image prostate cancer with PET as well as provide intra-operative surgical guidance through fluorescence (optical) imaging. Image-guided (fluorescence) imaging is a standard embedded feature of modern robotic surgery platforms (e.g. the Firefly® imaging system as part of the da Vinci® surgical robotics system by Intuitive Surgical), extensively used in urologic surgery worldwide.Under the terms of the collaboration, Telix will collaborate with DKFZ and affiliated researchers to conduct the necessary translational research studies to evaluate the technology in the surgical setting. The agreement includes a fully negotiated, exclusive option to license the technology for commercial development. The principal investigator at DKFZ, Dr. Ann-Christin Baranski, and who is also a scientist of the German Cancer Consortium (DKTK, partner location Freiburg) and the department of Nuclear Medicine (University Hospital Freiburg) added, “Our colleagues at Telix have made tremendous progress in commercializing PSMA-11 PET imaging, a technology that was originally developed here at DKFZ. To this end, Telix we feel Telix is an appropriate commercial partner for this novel technology and we look forward to working with the Telix team to evaluate the impact of this technology in patients in the near future.”

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Strategic Alliance in FDC for Cancer Treatment

Posted by fidest press agency su domenica, 4 agosto 2019

Biotechnology company Antikor Biopharma Ltd is pleased to announce that it has entered into an Investment Agreement for up to US$3,100,000 with Essex Bio-Investment, a wholly-owned subsidiary of Essex Bio-Technology Ltd (”EssexBio”), which will enable Antikor to consolidate and expand its position as a leading innovator in smaller-format conjugate therapies for solid tumours.Mahendra Deonarain, Antikor’s CEO and visiting Reader in Antibody Technology at Imperial College London where Antikor has its roots, commented: “We believe we have a platform that is tailored to make an impact in an area of major unmet medical need, and with EssexBio’s considerable commercial and clinical expertise, we now have the opportunity for translating the promised advantages of Antikor’s proprietary products into clinical benefit.”“We are excited to have established a strong alliance with Antikor”, said Malcolm Ngiam, President of Essex Bio-Investment, “Fragment-Drug Conjugate is an innovative approach with the potential to overcome many of the challenges faced by current treatment methods. The research and commercial partnership with Antikor is an important step towards developing first-in-class treatment for cancer.” Antikor’s novel technology platform will enrich Essex’s research pipeline and is aligned with EssexBio’s long-term research and commercial strategy.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer

Posted by fidest press agency su domenica, 4 agosto 2019

Transgene (Paris:TNG), a biotech company designing and developing virus-based immunotherapies for the treatment of solid tumors, today announces that the independent Data Monitoring Committee (“IDMC”) of the PHOCUS study of Pexa-Vec in Liver Cancer has completed a planned interim futility analysis. Sillajen has informed Transgene of the IDMC’s recommendation to stop enrolment in the study, as the study is unlikely to meet its primary objective by the time of the final analysis. SillaJen has not reported safety concerns. Transgene will provide an update in an upcoming conference call.
The PHOCUS trial is a Phase 3 clinical trial evaluating the oncolytic immunotherapy Pexa-Vec for advanced liver cancer patients who have not received prior systemic treatment for their cancer. The study is being conducted by Transgene’s partner, SillaJen.In the PHOCUS study, patients were randomized to one of two treatment groups: one receiving Pexa-Vec followed by sorafenib and one receiving sorafenib alone. The primary objective of the study was to determine the overall survival of patients treated with Pexa-Vec, followed by sorafenib versus sorafenib alone. Secondary objectives included safety as well as assessments for tumor responses between the two groups as measured by the following endpoints: time to progression, progression-free survival, overall response rate and disease control rate.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung Cancer

Posted by fidest press agency su giovedì, 27 giugno 2019

OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with the most current and insightful information they need to provide the best patient care, will host its latest State of the Science Summit™ on Non-Small Cell Lung Cancer (NSCLC) Monday, July 1, from 5-9 p.m. at the Whitley in Atlanta. The summit will be chaired by Suresh S. Ramalingam, MD, FASCO, deputy director, assistant dean for cancer research, director of the lung cancer program and, co-leader of the discovery and developmental therapeutics program at Winship Cancer Institute of Emory University.
This interactive and educational meeting will discuss novel treatments for patients with NSCLC. Expert presenters will delve into informative topics facing lung cancer specialists, oncologists, nurses and other medical professionals, such as screening for NSCLC, stage 1c squamous and nonsquamous NSCLC, EGFR-positive NSCLC, ALK-positive and ROS1 NSCLC, and targetable biomarkers in NSCLC. The presenters will also engage in a peer exchange and address audience questions.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

State of the Science Summit on Non-Small Cell Lung Cancer

Posted by fidest press agency su mercoledì, 12 giugno 2019

OncLive®, the nation’s leading digital resource focused on providing oncology professionals with the most current and insightful information they need to offer the best patient care, will host its latest State of the Science Summit™ on non-small cell lung cancer (NSCLC) on Monday, June 17, from 5 to 9 p.m. at the Boston Marriott Newton in Newton, Massachusetts. The summit will be chaired by Dr. Lecia V. Sequist, Landry Family associate professor of medicine at Harvard Medical School and director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital.
This interactive and educational meeting will discuss novel treatments for patients with NSCLC. Expert presenters will delve into informative topics facing lung cancer specialists, oncologists, nurses and other medical professionals, such as lung cancer screening, radiation oncology, stage 3 NSCLC, stage 4 small-cell lung cancer management, EGFR-positive lung cancer management, ALK-positive lung cancer management and emerging biomarkers in NSCLC. The presenters will also engage in a peer exchange and address audience questions.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Focused on building quality cancer care products

Posted by fidest press agency su lunedì, 3 giugno 2019

Lugano, Switzerland, June 1, 2019 – Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, in conjunction with the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO), today announces Allison Barz Leahy, MD, University of Pennsylvania, as the recipient of the Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care for 2019.
Conquer Cancer’s Young Investigator Award (YIA) funds physicians who are in the final years of training to aid their transition from a fellowship program to a faculty appointment. The YIA is a one-year $50,000 grant that aims to promote quality research in clinical oncology.The recipient of this endowed YIA, Dr. Allison B. Leahy, received her medical degree from SUNY Upstate College of Medicine. She completed her Pediatric Residency and Pediatric Hematology/Oncology Fellowship at the Children’s Hospital of Philadelphia (CHOP). Dr. Leahy is a recent alumna of the Pediatric Hospital Epidemiology and Outcomes Research Training program managed by the Center for Pediatric Clinical Effectiveness at CHOP and is currently finishing her thesis work for her Master of Science in Clinical Epidemiology from the University of Pennsylvania. Dr. Leahy’s clinical interests include investigating the benefits and barriers of using patient-reported symptom monitoring for children with cancer in an attempt to examine the impact of this type of monitoring on the quality of life, hospitalization rate and illness severity in childhood cancer. Dr. Leahy’s YIA project is entitled Symptom monitoring using patient-reported outcomes in newly diagnosed pediatric cancer patients.Established in 2016, the endowed YIA honors the life of Anna Braglia, the wife of Helsinn Group Founder and Chairman Gabriele Braglia and mother of Helsinn Group Vice Chairman and CEO Riccardo Braglia, who passed away in 2015. Helsinn endowed this award, which is part of Conquer Cancer’s ’s Grants and Award’s Program, to encourage more aspiring physicians to move into all areas of oncology by supporting them as they move from academia into research.Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “Dr. Allison Leahy is an exceptional candidate for this award. Her work on patient-reported outcomes in childhood cancer has the potential to dramatically improve the quality of life for cancer care in children. At Helsinn, we strive to improve the standard of living for individuals with cancer. Dr. Leahy’s work aligns with our goals and visions to put the patient at the heart of the approach cancer care and we are delighted to be able to support her invaluable work. We wish Dr. Leahy the best with her project”
Helsinn is a privately-owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland and the U.S., a representative office in China as well as a product presence in approximately 190 countries globally.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »